Juncai (Chris) Bai, Ph.D.

Founder and Chairman of the Board

Dr. Bai is also Founder and Chairman of AmbioPharm and Ambio. He was President and Chief Executive Officer of American Peptide Company and Senior Scientist of Abbott Laboratories in his prior career. Dr. Bai has over 30 years' experience in process development, scale-up and manufacturing of peptide and oligonucleotide. He has been instrumental on helping numerous biotech companies in drug candidate selection, manufacturing process design and regulatory application.

Ji (Stephen) Shen

Co-founder, Chief Executive Officer

With over ten years of experience in biotechnology and pharmaceutical industries, he is responsible for both managing operations and business development for ABR. Prior to starting ABR, he had long career at AmbioPharm, where he held a variety of positions at sales & business development, project management and regulatory support. He assisted of dozens of projects going through pre-clinical, clinical and commercialization successfully when at AmbioPharm.

Chengjia Peng

Co-founder, R&D Leader

With a strong background in Applied Chemistry, Mr. Peng is responsible for the upstream process development at ABR. He has over fifteen years of experience in peptide synthesis deriving from his career at Genscript and AmbioPharm. During his tenure, he successfully led and managed over 4,000 peptide projects for pharmaceutical use, ranging from linear short peptide to complex modified peptide containing disulfide bonds, stapled constraint, hydrophobic property or hydrophilic property. He is passionate about the innovation and has deep understanding about the process development in a breakthrough way.

Huaxing Shen

Co-founder, R&D Leader

Mr. Shen has extensive experience in biopharmaceutical manufacturing and operations, and is overseeing the downstream purification at ABR. With over 20 years of experience at downstream process, he has successfully led the manufacturing for over 4,000 peptide projects of the diverse complexity. He was involved in the process development for Glucagon, Liraglutide, Tirzepatide, Plecanatide and many complex peptides.